Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

281. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis

Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

282. Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention (Abstract)

Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention With femoral access, bivalirudin decreases risks of major bleeding after percutaneous coronary intervention (PCI) and provides better net clinical benefit compared to unfractionated heparin (UFH) plus planned glycoprotein IIb/IIIa inhibitors. Whether this benefit exists compared to UFH monotherapy is less clear. We performed a systematic review and meta

2012 EvidenceUpdates

283. Heparin-induced skin lesions. (Abstract)

Heparin-induced skin lesions. Heparins are widely used for prophylaxis and treatment of thromboembolic diseases. Besides bleeding complications, heparin-induced skin lesions are the most frequent unwanted adverse effects of subcutaneous heparin treatment. Evidence suggests that these lesions are more common than previously thought. Lesions are most frequently due to either allergic reactions or to possibly life-threatening heparin-induced thrombocytopenia. Early recognition and adequate (...) treatment are highly important, because although both complications initially show a similar clinical picture, their treatment should be fundamentally different. Furthermore, risk factors associated with the patient, drug, and treatment regimen have been identified. We review the clinical range of heparin-induced skin lesions, emphasise evidence and controversies in epidemiology, diagnosis, and differential diagnosis, and discuss the management of patients with these skin lesions.Copyright © 2012

2012 Lancet

284. The treatment of venous thromboembolism with low-molecular-weight heparins. A meta-analysis. (Full text)

The treatment of venous thromboembolism with low-molecular-weight heparins. A meta-analysis. The currently recommended method of venous thromboembolism (VTE) treatment is the application of vitamin K antagonists (VKA) in most patients, and low-molecular-weight heparins (LMWH) in selected groups. The VKA dose adjustment is difficult which might well render the treatment ineffective. The study aimed to compare LMWH with VKA in treating VTE in terms of efficacy and safety. A systematic review

2012 Thrombosis and haemostasis PubMed abstract

285. Early intravenous unfractionated heparin and mortality in septic shock

Early intravenous unfractionated heparin and mortality in septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

286. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis (Full text)

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Wilbur K, Lynd LD, Sadatsafavi M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low-dose unfractionated heparin versus low-molecular weight heparin (LMWH) for the prevention of venous thromboembolism, in patients hospitalised for non-surgical

2012 NHS Economic Evaluation Database. PubMed abstract

287. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction (Full text)

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.Cost-utility analysis with life-long time horizon.Costs, quality

2012 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

288. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. (Abstract)

Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. One of the most frequent and serious complications of endoscopic retrograde cholangiopancreatography (ERCP) is acute pancreatitis. The aim of this study was to evaluate the preventive effect of low-dose heparin (unfractionated or low-molecular-weight heparin) on post-ERCP pancreatitis (PEP) and its side-effects by a systematic review and meta-analysis (...) of clinical trials. Searching PubMed and EMBASE, up to August 2011, two independent reviewers systematically identified prospective clinical trials detecting the effect of prophylactic low-dose heparin on the incidence of PEP, severe PEP, and post-ERCP hemorrhage complications. Four clinical trials fulfilled our selection criteria, with three prospective randomized and one nonrandomized. A meta-analysis of these clinical trials was then performed. A total of 1438 patients were included. Meta-analysis

2012 European journal of gastroenterology & hepatology

289. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Silvain J, Beygui F, Barthelemy O, Pollack C, Cohen M, Zeymer U, Huber (...) K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G CRD summary The review concluded that enoxaparin seemed to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention, particularly for primary intervention in patients with ST elevation myocardial infarction. The authors' conclusions appear reasonable and are likely to be reliable. Authors' objectives To determine the efficacy and safety of enoxaparin compared

2012 DARE.

290. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

291. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients (Abstract)

A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients Central venous catheters (CVCs) are used for vascular access in hemodialysis patients who have no alternative access or are awaiting placement or maturation of a permanent access. The major complications of CVCs are catheter-related bloodstream infection and clotting in the catheter lumen.Parallel-group, randomized, multicenter clinical trial, with patients blinded (...) to study intervention.16 free-standing dialysis facilities in Northern California belonging to a single provider. 303 adult maintenance hemodialysis patients who were using a tunneled cuffed CVC for vascular access.The treatment group received an antibiotic lock containing gentamicin 320 μg/mL in 4% sodium citrate, whereas the control group received the standard catheter lock containing heparin 1,000 U/mL. Both groups received triple-antibiotic ointment on the catheter exit site during dressing changes

2012 EvidenceUpdates Controlled trial quality: uncertain

292. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

293. Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. (Abstract)

Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. It was the objective of this study to obtain best estimates of the prevalence of anti-PF4/heparin antibodies in patients not suspected to have clinical heparin-induced thrombocytopenia (HIT) prior to undergoing cardiac surgery and to determine whether preoperative antibody status and antibody class is predictive of postoperative thromboembolic outcomes, non (...) -thromboembolic outcomes, length of stay, and mortality. PubMed and EMBASE online databases were searched up to July 2011, and we included studies involving adults undergoing cardiac surgery examining the relationship between preoperative anti-PF4/heparin antibodies (ELISA) and postoperative clinical outcomes. Five studies involving a combined total of 2,332 patients met our inclusion criteria. Preoperative anti-PF4/heparin antibodies were detected in 5-22% of patients. No study demonstrated an association

2012 Thrombosis and haemostasis

294. Diagnosis and management of Heparin induced thrombocytopenia: second edition

Diagnosis and management of Heparin induced thrombocytopenia: second edition Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition - Watson - 2012 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines (...) on the diagnosis and management of heparin‐induced thrombocytopenia: second edition Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail: Royal Brompton Hospital, London, UK Oxford University Hospitals, Oxford, UK Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail

2012 British Committee for Standards in Haematology

295. Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care

Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care] Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic (...) disease with low molecular weight heparins in adult patients in home care] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Urtasun M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi

2012 Health Technology Assessment (HTA) Database.

296. Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline

Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Article Text Child health Randomised controlled

2012 Evidence-Based Nursing

297. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients (Abstract)

A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients Diagnosing postoperative heparin-induced thrombocytopenia (HIT) in cardiothoracic surgical patients is complicated because of the profound thrombocytopenia that occurs with cardiopulmonary bypass (CPB). CPB predisposes patients to develop a frequent incidence of antibodies directed against platelet factor 4 (PF4)/heparin complexes and HIT (...) . The sensitivity of readily available antibody immunoassays is high, but specificity is quite low. The use of both a clinical probability score and rapid laboratory immunoassay has been shown to increase specificity, which is of particular importance in the CPB setting. Prompt diagnosis is crucial because cessation of heparin and treatment with alternative anticoagulation can reduce the risk of thromboembolic events.We retrospectively reviewed records from cardiothoracic surgical patients whose serum

2012 EvidenceUpdates

298. [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]

[Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Pichon Riviere A, Augustovski F, Garcia (...) . [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°252. 2012 Authors' objectives To assess the evidence available on the safety, efficacy and other aspects related to coverage polices of the use of heparin-bonding vascular prosthesis for the treatment of peripheral artery occlusion. Authors' conclusions Short and long-term primary and secondary permeability rates

2012 Health Technology Assessment (HTA) Database.

299. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines. (Full text)

Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines. Early studies of glycoprotein IIb/IIIa inhibitors (GPIs) demonstrated benefit during percutaneous coronary intervention for acute coronary syndromes (ACS). Since their introduction, the magnitude of benefit of GPIs has become unclear.We hypothesized that adding a GPI (...) to unfractionated heparin in ACS patients treated with stents and thienopyridines is beneficial.We searched the MEDLINE, Cochrane, and clinicaltrials.gov databases for randomized clinical trials that studied the use of GPIs during ACS. We required that patients be randomly assigned to unfractionated heparin plus a GPI versus unfractionated heparin plus placebo (or control). Additional inclusion criteria included the use of coronary stents and periprocedural thienopyridines. Outcomes were assessed at 30 days

2012 Clinical cardiology PubMed abstract

300. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT (Full text)

Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT The optimal antithrombotic therapy for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention is not well defined. We investigated the efficacy and safety of bivalirudin versus heparin plus (...) a glycoprotein IIb/IIIa inhibitor (GPI) in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment.This study included 3798 clopidogrel-pretreated patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention, who were randomly assigned to receive bivalirudin (n=1928) or heparin (unfractionated heparin or enoxaparin; n=1870) plus a GPI in the setting of the Acute Catheterization

2012 Circulation. Cardiovascular interventions Controlled trial quality: predicted high PubMed abstract